We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Eylea

News List

NICE recommends Bayer's Eylea for myopic chorodial neovascularisation pharmafile
September 25, 2017
Bayer has revealed that UK drug regulator NICE has given its final recommendation on blockbuster eye drug Eylea in the treatment of visual impairment due to myopic chorodial neovascularisation
Avastin as effective as Eylea for treating central retinal vein occlusion cphi-online
May 15, 2017
NIH-funded clinical trial shows use of either drug improved vision and had few side effects.
Regeneron's annual outlook for Eylea sales growth falls short of expectations firstwordpharma
February 10, 2017
Regeneron Pharmaceuticals said Thursday alongside its fourth-quarter financial results that it expects US sales of Eylea to grow by a single-digit percentage this year, below analyst estimates.

Previous page 1 2 3 Next page